Pricing Log in Create free account
Saturday 17 October 2026 Export MRNA’s income statement to Excel — free account

Moderna, Inc.

MRNA Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.

218.01 18.49 −7.82%
Market cap
$94.4B
P/E
0.0×
Fwd P/E
−5.5×
Dividend yield
—
F-score
3/9
Altman Z
2.46
Beneish M
−3.52
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Moderna, Inc. (MRNA) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Moderna, Inc. (MRNA) trades at a EV/Sales of 36.9×. Over the past ten years it has ranged from −2.6× (January 2019) to 521× (May 2020); the current reading is higher than 77% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 3.2× 16.45%
FY2024 2.8× (45.62%)
FY2023 5.1× 59.76%
FY2022 3.2× (36.02%)
FY2021 5.0× (88.64%)
FY2020 44.0× (51.23%)
FY2019 90.2× —
FY2018 −2.1× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 10.5× 50.67%
Mar 2026 7.0× 115.05%
Dec 2025 3.2× 28.91%
Sep 2025 2.5× 37.65%
30 more quarters

Against its own ten years

Low −2.6× High 521×
Ten-year median 5.0×
Current reading's percentile 77

EV/Sales against peers

Company EV/Sales
REGN Regeneron Pharmaceuticals, Inc. compare 4.9×
ALNY Alnylam Pharmaceuticals, Inc. compare 6.0×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 6.1×
ARGX argenex SE compare 8.9×
VRTX Vertex Pharmaceuticals Incorporated compare 9.5×
RPRX Royalty Pharma PLC compare 14.0×
MRNA Moderna, Inc. 36.9×
RVMD Revolution Medicines, Inc. compare 1,287×
ROIV Roivant Sciences Ltd. compare 2,742×
Biotechnology industry median 9.2×
Healthcare sector median 3.4×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on MRNA